Oxford Nanopore Technologies Shares Rise: Poised for Continued Growth After Strong 2025 Performance

Oxford Nanopore Technologies (LON: ONT) shares rallied more than 12% in early Monday trading after the company announced a strong trading update for the full year 2025, signaling continued momentum and progress toward profitability.

The company anticipates reporting revenue slightly ahead of its previous guidance, bolstering confidence in its strategic direction.

The Group expects to report revenue of approximately £223 – £224 million for the year, a notable increase from the £183.2 million reported in FY24. This represents growth of approximately 22% on a reported basis and 24% at constant currency, exceeding the previously issued guidance range of 20-23% constant currency growth.

This broad-based growth was evident across all geographical regions, customer end markets, and product categories. Each region (EMEAI, APAC, and AMR) experienced revenue growth exceeding 20% at constant currency, demonstrating the company's expanding global footprint.

Clinical revenue demonstrated particularly strong growth, increasing by approximately 60% on a reported basis. BioPharma revenue grew by approximately 30%, while Applied Industrial revenue increased by approximately 27%. Research revenue also saw growth of approximately 15%, despite ongoing funding pressures within that end-market.

The PromethION range of products led the company's growth, with revenue increasing by more than 40% year-on-year on a reported basis. This highlights the increasing adoption of Oxford Nanopore's high-throughput sequencing technology.

Oxford Nanopore ended the year in a strong financial position, with approximately £302 million in cash, cash equivalents, and other liquid investments as of December 31, 2025. This figure is ahead of consensus expectations, aided by improvements in working capital, and provides a solid foundation for executing the Group's strategy. The FY24 figure was £403.8 million.

The company has scheduled the release of its preliminary annual results for the twelve months ended December 31, 2025, on Monday, March 2, 2026. Management will host a virtual presentation and Q&A session on the same day.